NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I'd like to ask a question as clearly I know nothing about patent law. It was pointed out elsewhere that Poly-ICLC is near the point where it goes off patent. The question is, can the patent be extended by proving it's benefits when used with DCVax-L?

If such an extension is possible, I could see substantial value in Onclovir, but without it, is there any real advantage to NWBO to acquire or partner with Oncovir if generic Poly-ICLC could be available shortly, or perhaps NWBO could actually make it themselves.

It seems to me that discussion had been made that if Keytruda worked with DCVax-L it could extend it's patent life, if that's true, the same should be true of Onclovir and Poly-ICLC.

For the people who developed Poly-ICLC I would hope this does benefit them, but if it comes completely off patent and can be easily made, it may be a blockbuster product that they fail to benefit that much from unless they're willing to sell it for less than competitors.

Gary